Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mechanisms of the effectiveness of poly(epsilon-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment

Full text
Author(s):
Claret Pereira, Natalia Rubio [1] ; Loiola, Rodrigo Azevedo [1] ; Rodrigues, Stephen Fernandes [1] ; de Oliveira, Catiuscia P. [2] ; Buttenbender, Sabrina L. [3] ; Guterres, Silvia S. [2] ; Pohlmann, Adriana R. [3] ; Farsky, Sandra H. [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, 580 Cidade Univ, BR-05508000 Sao Paulo, SP - Brazil
[2] Univ Fed Rio Grande do Sul, Fac Pharm, Porto Alegre, RS - Brazil
[3] Univ Fed Rio Grande do Sul, Inst Chem, Dept Organ Chem, Porto Alegre, RS - Brazil
Total Affiliations: 3
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF NANOMEDICINE; v. 13, p. 4563-4573, 2018.
Web of Science Citations: 3
Abstract

Purpose: The low penetration of drugs across the blood-brain barrier (BBB) compromises the delivery of chemotherapeutic agents to the brain parenchyma and contributes to the poor prognosis of glioblastoma multiforme (GBM). We investigated the efficacy of methotrexate-loaded lipid-core nanocapsules (MTX-LNC) administered by the oral route to treat murine GBM, its ability to cross the BBB, and the mechanisms of MTX-LNC uptake by cultured GL261 glioma and BV2 microglia cells. Materials and methods: Female C57B/6 mice were used in intravital microscopy assays to investigate the penetrance of rhodamine B-label MTX-LNC (RhoB/MTX-LNC) in the brain after oral or IV administration, and to evaluate the BBB integrity. Intracranial implantation of GL261 cells was undertaken to induce a murine GBM model, and the effectiveness of oral MTX or MTX-LNC treatments (started on Day 10 of GBM, every 2 days for 12 days) was quantified by tumor size, body weight, and leukogram. Pharmacological blockade of endocytic pathways was done to investigate the mechanisms of MTX-LNC uptake by cultured GL261 and microglia BV2 cells by using fluorescence microscopy. The effect of MTX-LNC or MTX on GL261 and BV2 proliferation was evaluated to compare the cytotoxicity of such compounds. Results: RhoB/MTX-LNC was detected in brain parenchyma of mice after IV or oral administration, without any damage on BBB. Oral treatment with MTX-LNC reduced tumor volume and prevented weight loss and leukopenia in comparison to MTX-treated mice. MTX-LNC uptake by GL261 is caveolae-dependent, whereas endocytosis of MTX-LNC by BV2 occurs via phagocytosis and macropinocytosis. Both MTX-LNC and MTX reduced GL261 and BV2 proliferation; however, MTX-LNC showed higher efficacy in the inhibition of glioma proliferation. Conclusion: Together, we infer that the higher ability of MTX-LNC to cross the BBB and be captured by cancer and immune brain cells by different mechanisms is responsible for the higher efficacy of oral MTX-LNC treatment in GBM. (AU)

FAPESP's process: 11/02438-8 - THERAPEUTIC EFFICACY OF INDOMETHACIN AND INDOMETHACIN ETHYL ESTER NANOCAPSULES IN THE CEREBRAL MICROCIRCULATION OF MICE: IN VIVO AND EX VIVO STUDIES
Grantee:Stephen Fernandes de Paula Rodrigues
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 14/07328-4 - Identification of endogenous pathways for the control of inflammation
Grantee:Sandra Helena Poliselli Farsky
Support Opportunities: Research Projects - Thematic Grants